VANCOUVER, BC--(Marketwire - July 09, 2008) - Upstream Biosciences Inc. (OTCBB: UPBS) today announced that it has entered into a collaboration with McGill University’s Institute of Parasitology in Montreal, Quebec, Canada to begin in vitro testing of the Company’s second generation of drug candidates for the potential treatment of tropical diseases leishmaniasis, trypanaosomiasis (African sleeping sickness) and malaria.
